DeepMind AI Identifies Senhwa Drug Candidate for Cancer Immunotherapy

October 21, 2025
Google DeepMind’s biological AI system has identified Senhwa Biosciences’ investigational drug Silmitasertib (CX-4945) as a promising molecule for enhancing immune response against tumors, according to a press release. The discovery, developed with Yale University, was experimentally validated and may open a new path in cancer immunotherapy.

Google’s DeepMind has identified Senhwa Biosciences’ investigational drug Silmitasertib (CX-4945) as a potential pathway for cancer immunotherapy, announced in a press release. The finding came from DeepMind’s C2S-Scale model, developed in collaboration with Yale University, which analyzed tumor cell data and over 4,000 drug candidates.

The AI model predicted that inhibiting protein kinase CK2 with CX-4945 could significantly increase MHC-I expression and antigen presentation—key processes that help the immune system detect tumor cells. Laboratory results confirmed that treatment with CX-4945, combined with low-dose interferon, improved antigen presentation by around 50%.

Silmitasertib, a first-in-class CK2 inhibitor, is in clinical development for multiple cancer types and has shown a favorable safety record in patients. DeepMind’s validation of CX-4945 underscores its potential to enhance immune visibility of “cold” tumors, offering a new direction for immuno-oncology research.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

10/21
Hyro Raises $45 Million to Expand AI Agents for Healthcare
10/21
DrugBank Appoints Lisa Downey as CEO, Co-Founder Mike Wilson Moves to Chief Product Role
10/21
Lightbeam Health Solutions Reports $444 Million in ACO Savings for 2024
10/21
Brook.ai Names Former Teladoc COO Mike Waters as Chairman of the Board
10/21
Tri-City Cardiology Expands AI Partnership with Basata

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like